Cellular Biomedicine, a New York-Shanghai company, has started a China Phase I trial of its CD20 CAR-T candidate in patients who relapsed after CD19 treatment. The patients have either relapsed diffuse large B-cell lymphoma or small B-cell lymphoma. The Phase I trial will enroll an initial 12 patients to evaluate the treatment’s safety and efficacy. In addition, Cellular Bio is close to starting trials for its Alpha Fetoprotein T-cell Receptor candidate in liver cancer and its next-gen Tumor Infiltrating Lymphocytes in non-small cell lung cancer patients.
Source: China Biotoday
